What are the key financial performance indicators reported in this 10-Q?

This 10-Q details the Consolidated Statements of Earnings and Comprehensive Income, providing data on revenues, cost of sales, operating expenses, and net earnings for the period. Investors should examine these figures to understand the company's profitability and revenue trends during the first quarter of 2019.

What are the primary risks and legal matters mentioned in the filing?

Part II of the filing, specifically Item 1 (Legal Proceedings) and Item 1A (Risk Factors), outlines any ongoing legal disputes and potential risks that could impact BMY's business, financial condition, or results of operations. Investors should review these sections for potential headwinds or liabilities.

Where can I find information on the company's cash flow and liquidity?

The Consolidated Statements of Cash Flows, included in Part I, provides a detailed view of the company's cash generated from and used in operating, investing, and financing activities. This is crucial for assessing BMY's liquidity and its ability to fund operations and strategic initiatives.

What is the significance of the 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section?

This section (Item 2) is vital as it offers management's perspective on the company's financial performance and condition. It provides context and analysis behind the numbers, helping investors understand trends, significant events, and the company's outlook.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2019

Summary

Bristol Myers Squibb (BMY) filed its 10-Q for the period ending March 30, 2019, reporting on its financial performance and operational highlights. The company is navigating a significant period of transition, likely influenced by ongoing strategic initiatives and market dynamics within the biopharmaceutical industry. Investors should pay close attention to revenue drivers, pipeline developments, and any updates on strategic partnerships or acquisitions which are critical for future growth. The filing provides a snapshot of the company's financial health, operational efficiency, and its forward-looking strategies for sustained value creation.

Financial Highlights

57 data points

Beta

Revenue

$5.92B

0.7% Gross Margin

Net Income

$1.71B

0.3% Net Margin

EPS (Diluted)

$1.04

Total Assets

$34.83B

Cash & Equivalents

$7.33B

Free Cash Flow

$1.19B

Financial Statements

Beta

Revenue	$5.92B
Cost of Revenue	$1.82B
Gross Profit	$4.10B
R&D Expenses	$1.35B
SG&A Expenses	$1.01B
Operating Expenses	$3.94B
Interest Expense	$45.00M
Net Income	$1.71B
EPS (Basic)	$1.05
EPS (Diluted)	$1.04
Shares Outstanding (Basic)	1.63B
Shares Outstanding (Diluted)	1.64B

Key Highlights

1The filing covers the first quarter of 2019, providing an updated view of BMY's financial performance post-year-end 2018.
2Key financial statements, including the Consolidated Statements of Earnings, Comprehensive Income, Balance Sheets, and Cash Flows, are presented.
3Management's Discussion and Analysis (MD&A) offers insights into the company's financial condition, results of operations, and liquidity.
4Disclosure regarding market risk provides information on how BMY manages exposure to fluctuations in interest rates, foreign currency exchange rates, and other market factors.
5The report includes information on legal proceedings, which could have material financial implications.
6Risk factors are updated, highlighting potential challenges and uncertainties that could affect the company's business and financial results.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2019

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions